As treatment options for Parkinson disease (PD) continue to expand, clinicians increasingly have to consider when patients ...
Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of ...
Unlike the antiseizure medications used to manage Dravet syndrome, which act on downstream targets to modulate seizure ...
Lundbeck recently announced that its Lu AF28996, an investigational oral prodrug of a D1-like/D2-like dopamine receptor agonist, was associated with increases in good ON-time and ...
The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of ...
Investigational oral dopamine agonist prodrug boosts good ON-time, cuts OFF-time and dyskinesia, and reduces levodopa in advanced Parkinson disease, as phase 2 begins. The associate vice president of ...
Cerebral palsy (CP) is the most common motor disability of childhood, a group of permanent movement disorders caused by a ...
On September 17, 2026, NeurologyLive convened a clinical forum in Philadelphia titled "Recognizing and Treating Plexiform ...
Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
Cluster headache care remains hindered by migraine overlap, contributing to diagnostic delay and prolonged unmet need for ...
Extracellular vesicle scores largely remained stable on placebo, whereas KP405 was associated with statistically significant but variable within-subject shifts in insulin signaling, neuroprotection, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results